Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Molecular Cancer Therapeutics|2025Cited by 20
Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumorsAntoine Simoneau, Teng Teng, Steven Lombardo et al.|Molecular Cancer Therapeutics|2025Cited by 2
Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitorsMatthew R. Tonini, Kimberly J. Briggs, Hannah Stowe et al.|Cancer Research|2024Cited by 1
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Teng Teng, Xuewen Pan et al.|Biochimica et Biophysica Acta (BBA) - Molecular Cell Research|2025Cited by 1
Abstract B078: APMAP functions as a tumor-intrinsic target sensitizing cancer cells to macrophage-mediated phagocytosisRachel Davidson, Serge Gueroussov, Ye Wang et al.|Cancer Immunology Research|2025Cited by 0